Merck

Lentiviral Vectors

Scientist working on gene therapy in laboratory

Enhancing Quality and De-risking Production for Cell & Gene Therapies

Leveraging our deep experience, knowledge, and expertise from three decades of viral vector development and manufacturing, our VirusExpress® lentivirus platform delivers a high performance, high quality solution to de-risk lentivirus production.

Using our VirusExpress® lentivirus platform, our technical experts can accelerate your path to clinical and commercial GMP manufacturing by providing  streamlined development, scalable manufacturing, and comprehensive analytics.

Talk to an Expert


Our Track Record

4 x 108 TU/mL

Industry-leading lentivirus titer

< 12

Months to GMP manufacturing

200+ L

Proven, streamlined scalability

300+

Batches of lentiviral vector produced

30

Years of viral vector development and manufacturing

1

One of the first to support commercially approved CAR-Ts


De-risked Lentivirus Production Through Experience

Providing high titer, high yield, and high quality products, our VirusExpress® lentivirus platform has been successfully used in numerous clinical programs. 

Partnering with us you gain an efficient and knowledgeable approach, and confidence in the quality of the clinical and commercial manufacturing of your lentiviral vector.

Our lentivirus platform is fully comprehensive and tailored to meet your timelines:

  • Packaging and transfer plasmids
  • GMP-banked HEK293T cell line
  • Chemically defined cell culture medium
  • Optimized GMP production
  • On-site fill/finish services
  • Comprehensive analytical toolbox
  • Regulatory support services

Lentivirus VirusExpress® Platform Advantages

Our team of development and manufacturing experts have successfully compressed project timelines and seamlessly scaled-up lentivirus cell and gene therapy programs through IND-submission and into clinical trials.

Proven Performance

A blue circle with a yellow checklist icon at its center, on a yellow background.
  • Successfully used in numerous clinical programs
  • Multiple INDs in process/filed

    Accelerated Timelines

    A blue circle with a yellow half-circle icon at its center and a yellow line pointing to the right of the half-circle, representing an acceleration, on a yellow background.
    • Less than 12 months to GMP manufacturing
    • Save 18 to 20+ months compared to a traditional process timeline

      Cost Savings

      A blue circle with a yellow US dollar icon at its center, on a yellow background.
      • Lower operational spend with more productive batches
      • Lower cost per dose

        Comprehensive Analytics

        A blue circle with a yellow magnifying glass icon at its center, showing three rising yellow bars with a yellow arrow above, representing a rise, on a yellow background.
        • In-house analytical testing
        • Fully qualified external network

          Our Experience is Your Success

          Trusted to advance lentiviral cell and gene therapies for three decades, we have the expertise and knowhow to support your therapeutic from preclinical development through commercialization.

          Contact us to discover how our lentivirus platform can de-risk and optimize your lentiviral vector program to improve performance, quality, reduce costs, and compress development to GMP manufacturing in less than 12 months.



          Related Resources


          Related Webinars

          Webinar: Streamlining Viral Vector Development and Manufacturing

          Hear from our viral vector experts as they showcase our capabilities and solutions for cell and gene therapy production and highlight key features of our technologies and GMP facility.

          Webinar: Industry-leading Lentiviral Titers Through our Optimized VirusExpress® Platform

          In this webinar, our innovation scientists explore how they optimized our VirusExpress® platform for lentiviral vectors to maximize titer, while providing a streamlined platform to accelerate development timelines to clinical trials.

          Webinar: Make More Lentivirus and Make it Right the First Time

          In this webinar we share how the superior performance of our scalable, end-to-end VirusExpress® lentivirus platform enables success for your cell or gene therapy.


          Sign In To Continue

          To continue reading please sign in or create an account.

          Don't Have An Account?